WolterKWagnerKPhilippTFritschkaE. Interaction between FK506 and clarithromycin in a renal transplant patient. Eur J Clin Pharmacol1994;47 (2):207–8.
2.
KunickiPKSobieszczaska-MałekM. Pharmacokinetic interaction between tacrolimus and clarithromycin in a heart transplant patient. Ther Drug Monit2005;27 (1):107–8.
3.
GómezGAlvarezMLErrastiPAcute nephrotoxicity in renal transplant patients treated with clarithromycin. Transplant Proc1999;31 (6):2250–1.
4.
OlyaeiAJde MattosAMBennettWM. Immunosuppressant-induced nephropathy. Drug Safety1999;21 (6):471–88.
5.
PageRL2ndMillerGGLindenfeldJ. Drug therapy in the heart transplant recipient: part IV: drug-drug interactions. Circulation2005;111:230–9.
6.
SpicerSTLiddleCChapmanJRThe mechanism of cyclosporine toxicity induced by clarithromycin. Br J Clin Pharmacol1997;43:194–6.
7.
LindenfeldJMillerGGShakarSFDrug therapy in the heart transplant recipient: part II: immunosuppressive drugs. Circulation2004;110:3848–65.
8.
ElbarbryFAMarfleetTShokerAS. Drug-drug interactions with immunosuppressive agents: review of the in vitro functional assays and role of cytochrome P450 enzymes. Transplantation2008;85 (9):1222–9.
9.
StrachanDBurtonIPearsonGJ. Is oral azithromycin effective for the treatment of cyclosporine-induced gingival hyperplasia in cardiac transplant recipients?J Clin Pharm Ther2003;28:329–38.
10.
RossHHendryPDipchandA. 2001 Canadian Cardiovascular Society Consensus Conference on Cardiac Transplantation. Can J Cardiol2003;19 (6):620–54.